MetaCap

Indivior Pharmaceuticals Cash Flow Statement

NASDAQ: INDVHealth CareBiotechnology: Pharmaceutical PreparationsUSD

35.83+0.38 (+1.07%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Indivior Pharmaceuticals free cash flow

In fiscal 2025, Indivior Pharmaceuticals generated -$27.0 million of operating cash flow and spent $66.0 million on capital expenditures. That left free cash flow of -$93.0 million, a free-cash-flow margin of -7.5% of revenue. Free cash flow was down 1428.6% from the prior year's $7.0 million.

Indivior Pharmaceuticals returned $11.0 million to shareholders through share repurchases.

Summary generated from market data by MetaCap's automated system. Methodology

Indivior Pharmaceuticals cash flow statement (annual)

Indivior Pharmaceuticals annual cash flow statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31
Net Income210.00M7.00M-126.00M-42.00M205.00M
Net Income growth (YoY)+2900.00%——-120.49%—
Depreciation & Amortization10.00M16.00M15.00M16.00M15.00M
Stock-Based Compensation26.00M24.00M21.00M16.00M11.00M
Change in Working Capital111.00M341.00M-347.00M-82.00M—
Operating Cash Flow-27.00M36.00M-300.00M-4.00M353.00M
Capital Expenditures-66.00M-29.00M-8.00M-5.00M-4.00M
Investing Cash Flow-66.00M69.00M-95.00M-222.00M-14.00M
Share Repurchases-11.00M-173.00M-33.00M-90.00M-101.00M
Debt Issued0332.00M00250.00M
Debt Repaid-17.00M-240.00M-12.00M-3.00M-236.00M
Financing Cash Flow-30.00M-102.00M-64.00M-101.00M-94.00M
Net Change in Cash-124.00M3.00M-459.00M-327.00M244.00M
Free Cash Flow-93.00M7.00M-308.00M-9.00M349.00M

This table shows 5 annual periods of Indivior Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2021, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow INDV's reporting calendar. What is a cash flow statement?

More financial data